Holen Sie sich die Stockscreener-App
128.32
3.10%
-4.10
Vorhandelsmarkt:
130.05
1.73
+1.35%
Schlusskurs vom Vortag:
$132.42
Offen:
$132.07
24-Stunden-Volumen:
760.31K
Relative Volume:
0.70
Marktkapitalisierung:
$12.88B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$478.60M
KGV:
27.49
EPS:
4.6676
Netto-Cashflow:
$748.70M
1W Leistung:
+0.50%
1M Leistung:
-2.97%
6M Leistung:
-9.63%
1J Leistung:
+12.56%
1-Tages-Spanne:
$128.02
$132.95
1-Wochen-Bereich:
$125.11
$133.04
52-Wochen-Spanne:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
128.32 | 12.88B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
17.91 | 56.58B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
113.35 | 47.85B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.80 | 43.75B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.74 | 33.47B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
522.83 | 22.91B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurocrine Biosciences Stock: A Leader in Neurological and Endocrine Therapies with Strong US Market - AD HOC NEWS
Wealth Enhancement Advisory Services LLC Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
Free cash flow per share of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
SG Americas Securities LLC Buys 119,339 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Nordea Investment Management AB Increases Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assenagon Asset Management S.A. Has $11.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
[SCHEDULE 13G/A] NEUROCRINE BIOSCIENCES INC Amended Passive Investment Disclosure - Stock Titan
Neurocrine (NASDAQ:NBIX) Expands Clinical Strategy As Nasdaq Futures Shift - Kalkine Media
Tudor Investment Corp ET AL Buys 23,893 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Is Geriatric-Focused INGREZZA Data Quietly Reframing Neurocrine Biosciences' Neurology Leadership Narrative (NBIX)? - Yahoo Finance
Neurocrine Biosciences Updates Tardive Dyskinesia Care And Valuation Story - simplywall.st
Neurocrine presents tardive dyskinesia treatment guidance for elderly - StreetInsider
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings - ChartMill
Earnings Miss: Why is Neurocrine Biosciences Inc stock going upProfit Target & Consistent Growth Equity Picks - baoquankhu1.vn
Shorts Report: Does Neurocrine Biosciences Inc have pricing powerTrend Reversal & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Neurocrine Biosciences Inc (NBIX) Shares Up 3.53% on Mar 25 - GuruFocus
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup - ChartMill
Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update - MSN
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Neurocrine Biosciences, Inc.Common Stock (NQ: NBIX - FinancialContent
CIBC Private Wealth Group Boosts Neurocrine Biosciences Stock Holdings - National Today
CIBC Private Wealth Group LLC Grows Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assessing Neurocrine Biosciences (NBIX) Valuation As Shares Soften Despite Growing Revenue And Net Income - Sahm
Block Trades: Can Neurocrine Biosciences Inc be recession proofProfit Target & Long Hold Capital Preservation Plans - baoquankhu1.vn
Hedge Fund Bets: Can Neurocrine Biosciences Inc maintain its current growth rateWall Street Watch & Safe Entry Trade Signal Reports - baoquankhu1.vn
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hudson Bay Capital Management LP - MarketBeat
If You Invested $1,000 in Neurocrine Biosciences Inc (NBIX) - Stock Titan
Neurocrine Biosciences Maps 2026 Execution, “Data-Rich” 2027; Ingrezza Guides $2.7B–$2.8B - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Case as a Quality Value Stock - ChartMill
Understanding the Setup: (NBIX) and Scalable Risk - Stock Traders Daily
Wolfe Research initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendation - MSN
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Neurocrine Biosciences promotes Andrew Ratz to operations chief By Investing.com - Investing.com South Africa
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Tec - GuruFocus
Neurocrine at Stifel CNS Forum: Growth and Strategic Focus - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2026 Virtual CNS Forum, Mar-17-2026 04 - marketscreener.com
Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants - Stock Titan
Neurocrine Biosciences promotes Andrew Ratz to operations chief - Investing.com
Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer - StreetInsider
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer - StreetInsider
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN
Neurocrine Biosciences: The Song Remains The Same (NASDAQ:NBIX) - Seeking Alpha
Iron Triangle Partners LP Acquires New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Distillate Capital Partners LLC Trims Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Boone Capital Management Decreases Stake in Neurocrine Biosciences - National Today
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Braidwell LP - MarketBeat
Boone Capital Management LLC Has $23.36 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
5.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):